publication date: Oct. 26, 2018
Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say:
Stuart B. Padnos Professor of Breast Cancer Research,University of Michigan Rogel Cancer Center
Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.
However, we still have much to learn—most specifically why checkpoint inhibition (CPI) works in some but not all cancers, and why it is so well tolerated in many patients but has life-taking/threatening toxicities in a few?
Because we have been siloed into tissue-of-origin treatment bins (melanoma, lung, colorectal, breast, etc) over the last 100 or more years, we have applied these therapies based more on where the cancer was derived than on the biology of the cancer itself. This is not inappropriate, since the biology of the cancer almost certainly reflects that of the normal tissue from which it grew.
This raises the question: why have the results of CPI been so spectacular in melanoma, lung, colorectal, and selected other cancers, but less than great in other … Continue reading Has Tecentriq earned a role in treatment of triple-negative breast cancer? Here is what experts say:
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.